97336 ⎘
Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
IL-15-BASED MOLECULES AND METHODS OF USE THEREOF
#2TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTOR
#3PD-L1 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
#4IL-15-BASED MOLECULES AND METHODS OF USE THEREOF
#5METHODS AND COMPOSITIONS RELATING TO TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
#6GD2 BI-SPECIFIC INVARIANT NATURAL KILLER T CELL ENGAGERS AND METHODS OF USE THEREOF
#7COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
#8LINEAR NUCLEIC ACID EXPRESSION CONSTRUCTS
#9ANTITUMOR IMMUNE CHECKPOINT REGULATOR ANTAGONISTS
#10ANTI-PVRIG ANTIBODIES AND METHODS OF USE
#11Method for the Induction of Arterial-Type of Hemogenic Endothelium from hPSCS
#12ANTI-PD-1 MONOCLONAL ANTIBODY, DERIVATIVE THEREOF AND USE THEREOF
#13IL-15-BASED MOLECULES AND METHODS OF USE THEREOF
#14IL-15-BASED MOLECULES AND METHODS OF USE THEREOF
#15CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#16BINDING-TRIGGERED TRANSCRIPTIONAL SWITCHES AND METHODS OF USE THEREOF
#17METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF
#18NUCLEIC ACIDS ENCODING SWITCH RECEPTORS USING IL-9 RECEPTOR SIGNALING DOMAINS
#19INTERLEUKIN-2/INTERLEUKIN-2 RECEPTOR ALPHA FUSION PROTEINS AND METHODS OF USE
#20Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders
#21SWITCH RECEPTORS USING IL-9 SIGNALING DOMAINS
#22PHARMACEUTICAL FORMULATIONS AND METHODS OF MAKING THE SAME
#23Bispecific FC Fusion Proteins with sPD-1 and IL-15
#24METHODS OF USE OF ANTI-SORTILIN ANTIBODIES FOR TREATING A DISEASE, DISORDER, OR INJURY
#25ALK4:ACTRIIB HETEROMULTIMERS AND USES THEREOF
#26Transgenic Macrophages, Chimeric Antigen Receptors, and Associated Methods
#27CD27 AGONISTS
#28Compositions and Methods for Treatment of Ocular Disease Associated with Angiogenesis
#29BCMA CHIMERIC ANTIGEN RECEPTORS
#30Methods And Systems For Producing A Protein Of Interest In A Plant
#31ANTIBODY MASKS AND USES THEREOF
#32BI-FUNCTIONAL FUSION PROTEIN AND USES THEREOF
#33VECTORIZED TNF-ALPHA ANTAGONISTS FOR OCULAR INDICATIONS
#34COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION
#35TREATMENT OF FIBROSIS
#36METHOD FOR PROMOTING BONE GROWTH USING ACTIVIN-ACTRIIA ANTAGONISTS
#37METHODS OF USE OF ANTI-SORTILIN ANTIBODIES FOR TREATING A DISEASE, DISORDER, OR INJURY
#38BCG and IL-15 based molecules
#39IL-15-based molecules with anti-CD20 antibody and methods of use
#40METHOD FOR STIMULATING TUMOR-INFILTRATING LYMPHOCYTES WITH AN IL-15:IL-15R COMPLEX
#41BISPECIFIC FUSION PROTEIN
#42INTERLEUKIN-15 BASED IMMUNOCYTOKINES
#43COMPOUNDS AND METHODS FOR TREATING PAIN
#44IL-15-BASED MOLECULES AND METHODS OF USE THEREOF
#45Compositions comprising IL-15N72D-based molecules and bacillus calmette-guerin (BCG)
#46PSGL-1 Antagonists and Uses Thereof
#47Compositions and Methods for Treatment of Ocular Disease Associated with Angiogenesis
#48CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#49USE OF IL-6 ANTIBODIES AND VEGF TRAPS, AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
#50METHODS AND COMPOSITIONS COMPRISING MHC CLASS I PEPTIDES
#51CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#52COMPOSITIONS AND METHODS FOR TREATING SPINAL MUSCULAR ATROPHY
#53Antigen Presenting Polypeptide Complexes Bearing TGF-Beta and Methods of Use Thereof
#54COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS
#55Compositions and Methods for Treatment of Ocular Disease Associated with Angiogenesis
#56CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#57Methods of treating a neoplasia with IL-15-based molecules and CTLA-4 antibody
#58Use of a VEGF antagonist to treat angiogenic eye disorders
#59Anti-PVRIG antibodies and methods of use
#60Novel Angiopoietin 2, VEGF Dual Antagonists
#61METHODS FOR EXPANDING IMMUNE CELLS
#62BIFUNCTIONAL ANTAGONISTS OF ACTIVIN AND TUMOR NECROSIS FACTOR ALPHA AND USES THEREOF
#63CHIMERIC ANTIGEN COMPRISING THE EXTRACELLULAR DOMAIN OF PD-L1
#64T CELL RECEPTOR-DEFICIENT CHIMERIC ANTIGEN RECEPTOR T-CELLS AND METHODS OF USE THEREOF
#65SOLUBLE TCRS AND FUSIONS TO ANTI-CD3 RECOGNIZING KRAS G12D FOR THE TREATMENT OF CANCER
#66MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER
#67Methods and compositions for transducing lymphocytes and regulating the activity thereof
#68VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER
#69ANTITUMOR IMMUNE CHECKPOINT REGULATOR ANTAGONISTS
#70COMBINED PREPARATIONS FOR THE TREATMENT OF CANCER OR INFECTION
#71Antibody Derivatives with Conditionally Enabled Effector Function
#72Switch receptors using IL-9 signaling domains
#73STABILIZED ANTIBODY PROTEIN SOLUTIONS
#74Nucleic acids encoding switch receptors using IL-9 receptor signaling domains
#75CHIMERIC ANTIGEN RECEPTOR-EXPRESSING IMMUNOCOMPETENT CELLS
#76IL-15-based molecules and methods of treating a neoplasia
#77Method for treating neoplasia with an anti-CD38 antibody and an IL-15:IL-15R complex
#78BISPECIFIC HETERODIMERIC FUSION PROTEINS CONTAINING IL-15 - IL-15Ralpha Fc-FUSION PROTEINS AND IMMUNE CHECKPOINT ANTIBODY FRAGMENTS
#79PD-L1 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
#80Compositions comprising IL-15-based molecules and immune checkpoint inhibitor antibodies
#81TUNING OF RELEASE KINETICS IN HYDROGELS
#82SINGLE-ARM ACTRIIA AND ACTRIIB HETEROMULTIMERS AND METHODS FOR TREATING RENAL DISEASES OR CONDITIONS
#83Multifunctional Heteromultimeric Constructs
#84BINDING PROTEINS USEFUL AGAINST ACE2-TARGETED VIRUSES
#85DESIGN AND DEVELOPMENT OF MASKED THERAPEUTIC ANTIBODIES TO LIMIT OFF-TARGET EFFECTS
#86Methods of treatment of arthritis and/or psoriasis with pharmaceutical formulations of etanercept
#87COMBINED PREPARATIONS FOR THE TREATMENT OF CANCER OR INFECTION
#88LONG LIFE POLYPEPTIDE BINDING MOLECULES
#89TARGETED PROTEIN CONTRAST AGENTS, METHODS OF MAKING, AND USES THEREOF
#90DUAL-CONTROLLED DRUG AND PHOTOACTIVATABLE SYSTEM FOR SPATIOTEMPORAL CONTROL OF CELL THERAPY
#91Multi-functional and multi-valent interleukin-TGF-beta receptor fusion polypeptides
#92INSERTABLE VARIABLE FRAGMENTS OF ANTIBODIES AND MODIFIED A1-A2 DOMAINS OF NKG2D LIGANDS
#93Methods and systems for producing a protein of interest in a plant
#94MULTISPECIFIC ANTAGONISTS
#95ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS
#96Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
#97SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
#98IL-2 COMPOSITIONS AND METHODS OF USE THEREOF
#99IL-2 FUSION PROTEINS THAT PREFERENTIALLY BIND IL-2RALPHA
#100METHODS OF NUCLEIC ACID SAMPLE PREPARATION
#101Use of a VEGF antagonist to treat angiogenic eye disorders
#102FUSION PROTEIN OF ETA ANTIBODY AND TGF-BETA TRAP AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF
#103ActRIIa and ALK4 polypeptides for treating kidney fibrosis, inflammation and injury
#104METHODS OF USE OF ANTI-SORTILIN ANTIBODIES FOR TREATING A DISEASE, DISORDER, OR INJURY
#105CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#106METHODS AND COMPOSITIONS COMPRISING ENHANCED TARGETED IMMUNE GENE THERAPY FOR THE TREATMENT OF CANCER
#107Modified AXL Peptides and Their Use in Inhibition of AXL Signaling in Anti-Metastatic Therapy
#108BIFUNCTIONAL FUSION PROTEIN AGAINST PDL1 AND TGFß AND USE THEREOF
#109ANTIBODIES AGAINST PROGRAMMED CELL DEATH PROTEIN 1 (PD1) AND USES THEREOF
#110Synthetic immune receptors and methods of use thereof
#111IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS
#112METHODS OF INCREASING PROGRANULIN LEVELS USING ANTI-SORTILIN ANTIBODIES
#113METHODS OF USE OF ANTI-SORTILIN ANTIBODIES FOR TREATING A DISEASE, DISORDER, OR INJURY
#114Multi-functional and multi-valent interleukin-TGF-beta receptor fusion polypeptides
#115TREATMENT OF OCULAR NEOVASCULARIZATION USING ANTI-VEGF PROTEINS
#116mRNA combination therapy for the treatment of cancer
#117Compositions and methods for treating spinal muscular atrophy
#118BISPECIFIC ANTIBODIES WITH TETRAVALENCY FOR A COSTIMULATORY TNF RECEPTOR
#119Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
#120ANTIBODIES AGAINST THE MUC1-C/EXTRACELLULAR DOMAIN (MUC1-C/ECD)
#121METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITION
#122IL4/IL13 Receptor Molecule for Veterinary Use
#123CELL CULTURE PROCESS FOR MAKING A GLYCOPROTEIN
#124CELL CULTURE PROCESS FOR MAKING A GLYCOPROTEIN
#125Methods of treatment of muscular dystrophy with ALK4:ActRIIB heteromultimers
#126Compounds and methods for treating pain
#127DECOY POLYPEPTIDES
#128Activatable IL2 composition and methods of use
#129Compositions and methods of treating cancer with chimeric antigen receptors
#130METHODS AND COMPOSITIONS RELATING TO TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
#131Use of a VEGF antagonist to treat angiogenic eye disorders
#132Use of a VEGF antagonist to treat angiogenic eye disorders
#133Method for the Induction of Arterial-Type of Hemogenic Endothelium from hPSCS
#134INHIBITORS OF P-TEFB MEDIATED TRANSCRIPTION
#135LIGAND-BINDING MOLECULE CONTAINING SINGLE DOMAIN ANTIBODY
#136Antitumor antagonists
#137SINGLE-CHAIN CD137-RECEPTOR AGONIST PROTEINS
#138Polypeptides
#139Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#140Transgenic macrophages, chimeric antigen receptors, and associated methods
#141CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#142Anti PD-1 antibodies
#143Anti-PVRIG antibodies and methods of use
#144Treatment of fibrosis
#145CTLA4-IG FUSION PROTEIN FORMULATION
#146Combined preparations for the treatment of cancer or infection
#147VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
#148IL-15 and IL-15R\alpha sushi domain based immunocytokines
#149Anti-human papillomavirus 16 E7 T cell receptors
#150Use of a VEGF antagonist to treat angiogenic eye disorders
#151COMBINATION THERAPY WITH TARGETED TGF-B INHIBITION FOR TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
#152Recombinant protein targeting PD-1 and TGFß
#153Cell comprising a chimeric antigen receptor or a transgenic T-cell receptor and comprising a chimeric TNF receptor
#154Use of a VEGF antagonist to treat angiogenic eye disorders
#155BCMA chimeric antigen receptors
#156BCMA chimeric antigen receptors
#157SINGLE-CHAIN CD27-RECEPTOR AGONIST PROTEINS
#158BCMA chimeric antigen receptors
#159Targeted protein contrast agents, methods of making, and uses thereof
#160BCMA chimeric antigen receptors
#161SINGLE-CHAIN CD40-RECEPTOR AGONIST PROTEINS
#162Use of a VEGF antagonist to treat angiogenic eye disorders
#163Trispecific antagonists
#164SOLUBLE FGFR3 DECOYS FOR TREATING SKELETAL GROWTH DISORDERS
#165Targeted protein contrast agents, methods of making, and uses thereof
#166HUMAN TNFRSF25 ANTIBODY
#167BCMA chimeric antigen receptors
#168Methods for treating pulmonary hypertension with a ligand binding domain of a TGF-beta type II receptor
#169Antibodies that specifically bind alpha klotho
#170TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTOR
#171Trispecific antagonists
#172CELL CULTURE PROCESS FOR MAKING A GLYCOPROTEIN
#173Light single-chain fusion polypeptides, encoding nucleic acid molecules and host cells
#174PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
#175Bifunctional compounds
#176Isolated nucleic acids encoding anti-sortilin antibodies
#177IL-11Rα antibodies
#178Polypeptides
#179Bispecific antagonist comprising a LAG-3 binding domain
#180Development of masked therapeutic antibodies to limit off-target effects
#181Therapeutic use of inhibitors of t cell activation or stimulation
#182Anti-PVRIG antibodies and methods of use
#183Peptide for toll-like receptor (TLR) inhibition and pharmaceutical composition comprising same
#184CELL CULTURE PROCESS FOR MAKING A GLYCOPROTEIN
#185Angiopoietin 2, VEGF dual antagonists
#186Bispecific heterodimeric fusion proteins containing IL-15-IL-15Ralpha Fc-fusion proteins and immune checkpoint antibody fragments
#187Compounds and methods for treating pain
#188Single-chain glucocorticoid-induced tumor necrosis factor receptor (GITR) receptor agonist proteins
#189Combined preparations for the treatment of cancer or infection
#190Serpin fusion polypeptides and methods of use thereof
#191Methods and compositions for treating ulcers
#192Deimmunized Serum-Binding Domains and Their Use in Extending Serum Half-Life
#193CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS
#194Vista modulators for diagnosis and treatment of cancer
#195Methods of treating cancer using bifunctional molecules that target growth factors
#196Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies
#197Soluble CD33 for treating myelodysplastic syndromes (MDS)
#198MRNA combination therapy for the treatment of cancer
#199IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS
#200Tuning of release kinetics in hydrogels
#201Anti PD-1 antibodies
#202Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#203ANTI-MCAM ANTIBODIES AND ASSOCIATED METHODS OF USE
#204THERAPIES BASED ON CONTROL OF REGULATORY T CELL STABILITY AND FUNCTION VIA A NEUROPILIN-1:SEMAPHORIN AXIS
#205Transgenic macrophages, chimeric antigen receptors, and associated methods
#206Trispecific antagonists
#207Antitumor antagonists
#208CD147 AS RECEPTOR FOR PILUS-MEDIATED ADHESION OF MENINGOCOCCI TO VASCULAR ENDOTHELIA
#209BCMA chimeric antigen receptors
#210BCMA chimeric antigen receptors
#211BCMA chimeric antigen receptors
#212BCMA chimeric antigen receptors
#213Multifunctional heteromultimeric constructs
#214PROTEINS BINDING BCMA, NKG2D AND CD16
#215Methods using GDF-15 antibodies for treatment of pulmonary arterial hypertension
#216Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
#217ACTRIIB-FC POLYNUCLEOTIDES, POLYPEPTIDES, AND COMPOSITIONS
#218CHIMERIC ANTIGEN RECEPTOR
#219Anti-PD-L1 antibody and IL-7 fusions
#220Method of identifying a P-selectin glycoprotein ligand-1 (PSGL-1) antagonist
#221COMPOSITIONS COMPRISING IL-2 FUSION PROTEINS AND METHODS FOR TREATING NEOPLASIA
#222Methods, arrangements and systems for obtaining information associated with an anatomical sample using optical microscopy
#223Fusion protein for treating Alzheimer's disease
#224Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use
#225Antibodies, combinations comprising antibodies, biomarkers, uses and methods
#226SOLUBLE TCR MOLECULES AND METHODS OF USE
#227ANTIBODIES DIRECTED AGAINST LYMPHOCYTE ACTIVATION GENE 3 (LAG-3)
#228Process for preparation of secretory IgA and secretory IgM
#229Use of a VEGF antagonist to treat angiogenic eye disorders
#230BISPECIFIC ANTIBODIES WITH TETRAVALENCY FOR A COSTIMULATORY TNF RECEPTOR
#231CTLA4 fusion proteins for the treatment of diabetes
#232Method for promoting bone growth using activin-actriia antagonists
#233CD40L single-chain fusion polypeptides and encoding nucleic acids
#234LONG LIFE POLYPEPTIDE BINDING MOLECULES
#235Modular, controlled single chain variable fragment antibody switch
#236GRP78 antagonist that block binding of receptor tyrosine kinase orphan receptors as immunotherapy anticancer agents
#237Anti-sortilin antibodies and methods of use thereof
#238TSLP inhibitors
#239Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab
#240Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#241Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#242Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#243Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#244Methods of increasing progranulin levels using anti-Sortilin antibodies
#245Anti-human papillomavirus 16 E7 T cell receptors
#246Methods of use of anti-Sortilin antibodies for treating a disease, disorder, or injury
#247METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITION
#248Use of a VEGF antagonist to treat angiogenic eye disorders
#249T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof
#250Antibodies which specifically bind αKlotho polypeptide
#251CD27 ligand (CD27L) single-chain fusion polypeptides
#252Pharmaceutical formulations and methods of making the same
#253CD27L collectin fusion proteins and encoding nucleic acids
#254Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
#255Treatment of fibrosis with interleukin-11 antibody
#256Deimmunized Serum-Binding Domains and Their Use in Extending Serum Half-Life
#257Treatment of fibrosis with interleukin-11 receptor alpha antibody
#258Treatment of fibrosis with interleukin-11 receptor alpha antibody
#259MRNA combination therapy for the treatment of cancer
#260Chimeric antigen receptor targeting human NKG2DL and methods of preparing said receptor and pharmaceutical composition
#261Treatment of fibrosis with interleukin-11 antibody
#262Treatment of fibrosis with interleukin-11 receptor alpha antibody
#263Treatment of fibrosis with IL-11 receptor alpha antibody
#264Treatment of fibrosis with Interleukin-11 receptor alpha antibody
#265Treatment of fibrosis with interleukin-11 receptor alpha antibody
#266Treatment of fibrosis with interleukin-11 antibody
#267Treatment of fibrosis with interleukin-11 antibody
#268Treatment of fibrosis with interleukin-11 antibody
#269Treatment of fibrosis with interleukin-11 antibody
#270Compounds for treating neurodegenerative proteinopathies
#271Binding-triggered transcriptional switches and methods of use thereof
#272Use of a VEGF antagonist to treat angiogenic eye disorders
#273Transgenic macrophages, chimeric antigen receptors, and associated methods
#274BINDING MEMBERS OF INTERLEUKIN-4 RECEPTOR ALPHA (IL4-Ra)
#275Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
#276Human TNFRSF25 antibody
#277IL-15 and IL-15Rα sushi domain based immunocytokines
#278TREATMENT OF OCULAR NEOVASCULARIZATION USING ANTI-VEGF PROTEINS
#279Method for the induction of arterial-type of hemogenic endothelium from hPSCS
#280Targeted protein contrast agents, methods of making, and uses thereof
#281Combined preparations for the treatment of cancer or infection
#282Anti-sortilin antibodies and methods of use thereof
#283IL-33 antagonists and uses thereof
#284Core constructs and their uses in configuring pharmaceutical molecules
#285Anti-PVRIG antibodies and methods of use
#286Single-chain TL1A receptor agonist proteins
#287Single-chain glucocorticoid-induced tumor necrosis factor receptor (GITR) agonist proteins
#288Single-chain CD27-receptor agonist proteins
#289Single-chain CD137-receptor agonist proteins
#290Compounds and methods for treating pain
#291Antibody derivatives with conditionally enabled effector function
#292Dual-target antibody targeting VEGFR-2 and DLL4 and pharmaceutical composition including same
#293Binding-triggered transcriptional switches and methods of use thereof
#294RAPID CLEARANCE OF ANTIGEN COMPLEXES USING NOVEL ANTIBODIES
#295Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
#296Methods for treating ulcers in a hemoglobinopathy anemia with a soluble actRIIB polypeptide
#297METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITION
#298ALK4.ActRIIB heteromultimers
#299Methods of nucleic acid sample preparation for immune repertoire sequencing
#300MULTIMERIC CONSTRUCTS